Aspergillus arthritis is a debilitating form of invasive aspergillosis. Little is known about its epidemiology, clinical manifestations, laboratory features, treatment, and prognosis. Cases of Aspergillus arthritis were reviewed in the English literature from 1967 through 2015 for variables of arthritis with Aspergillus spp. recovered from joint and/or adjacent bone, underlying conditions, symptoms, signs, inflammatory biomarkers, diagnostic imaging, management, and outcome. Among 31 evaluable cases, 87% were This work is written by (a) US Government employee(s) and is in the public domain in the US.
males and 13% pediatric. Median age was 50 y (range 1-83 y). Seventeen (55%) patients were immunosuppressed with such conditions as hematological malignancies (26%), corticosteroids (39%), and/or transplantation (26%). Approximately one-half (52%) of patients had hematogenous seeding of the joint, and more than 80% had de novo infection with no prior antifungal therapy. Oligoarticular infection (2-3 joints) occurred in 45% and contiguous osteomyelitis was present in 61%. Clinical manifestations included pain (87%), edema (26%), and limited function (23%), with knees (35%), intervertebral discs (26%), and hips (16%) being most commonly infected. Aspergillus fumigatus constituted 77% of cases followed by Aspergillus flavus in 13%, Aspergillus niger in 3%, and not specified in 7%. Median ESR was 90 mm/hr and median CRP was 3.6 mg/dl. Median synovial fluid WBC was 17,200/μL (7,300-128,000) with 72% PMNs (range 61-92). Osteolysis occurred in 35%, and soft-tissue extension 47%. Nineteen patients (61%) were managed with combined medical and surgical therapy, 10 (32%) with medical therapy only, and 2 (6%) surgery only. Amphotericin B and itraconazole were the most frequently used agents with median duration of therapy of 219 days (range . Surgical interventions included debridement in 61%, drainage 19%, and amputation 6%. Complete or partial response was achieved in 71% and relapse occurred in 16%. Medical therapy was reinstituted with successful outcome in these patients. Overall survival was 65%.
Introduction
Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients and an expanding population of otherwise apparently immunocompetent patients. Aspergillosis of the upper and lower respiratory tract, central nervous system, as well as skin and soft tissue structures have been well described. However, the musculoskeletal complications of invasive aspergillosis are not well understood. Although several recent reports underscore the increasing recognition of Aspergillus arthritis, little is known about this uncommon infection. [1] [2] [3] [4] In expanding our understanding of osteoarticular mycoses, the International Osteoarticular Mycoses Consortium sought to describe the characteristics and outcome of Aspergillus arthritis. We therefore completed a comprehensive review of 31 reported cases of Aspergillus arthritis that fulfilled prespecified criteria.
Patients and methods

Search strategy
The initial stage of the search strategy consisted of reviewing the English literature published in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) using the key words: Aspergillus, aspergillosis, arthritis, and osteomyelitis. We then carefully included only the well-described references of single case reports or case series. After this initial series of reports was reviewed, individual references listed in each publication were again reviewed for ascertainment of additional case reports and case series.
Study population
Only well-described reported cases of Aspergillus arthritis as published in the English literature within the study period 1967-2015 were included. Data regarding epidemiology, clinical and radiological features, demographic characteristics, management, and outcome of the patients were collected and presented with descriptive statistics to determine the risk factors of Aspergillus arthritis.
Criteria for inclusion of cases of Aspergillus arthritis
Cases selected in the initial screen were then included in the final analysis if the following data were available: demographics, underlying condition, level of documentation of Aspergillus arthritis, anatomical distribution of infection, symptomatology, clinical manifestations, inflammatory biomarkers, microbiology data, radiological findings, therapeutic intervention, and outcome.
Definitions
Direct inoculation
Seeding of synovial fluid by trauma or surgical manipulation.
Hematogenous
Seeding of synovial fluid by the blood-borne dissemination of organism from an extra-articular focus.
Contiguous
Seeding of synovial fluid from an adjacent Aspergillus infection.
Proven Aspergillus arthritis
Patient with evidence of a positive culture and/ or histology from synovial fluid analysis.
Probable Aspergillus arthritis
Patient with evidence of a positive culture, and/ or histology from other than a synovial fluid specimen, such as bone, cartilage, bone marrow, adjacent abscess, thrombus, tendon, disc, or operative samples, associated with compatible clinical and radiological features.
Breakthrough Aspergillus arthritis
Patient receiving systemic antifungal agents before or at the onset of Aspergillus arthritis.
De novo Aspergillus arthritis
Patient not receiving systemic antifungal therapy when the episode of Aspergillus arthritis occurred.
Complete response
Complete resolution of clinical and radiological findings of arthritis.
Partial response
Partial resolution of clinical and/or radiological findings of arthritis or partial clinical improvement without availability of radiological data. 
Data collection and analysis
Data regarding demographic characteristics, clinical manifestations, radiological features, inflammatory biomarkers, microbiology, medical therapy, surgical management, and outcome of patients were collected and analyzed with descriptive statistics using Instat GraphPad (GraphPad Software, San Diego, CA). Continuous variables were summarized using median and range while categorical variables were summarized using frequencies and percentages.
Results
Literature review
The first case of Aspergillus arthritis fulfilling the prespecified criteria was reported in 1976. 5 A total of 31 published cases of Aspergillus arthritis reported between 1976 and 2015 fulfilled predefined criteria for evaluability.
Demographic characteristics and underlying conditions
Among a total of 31 published cases of Aspergillus arthritis, median age was 50 y (range, 1-83 y), including four pediatric patients (Table 1) . Twenty-seven patients (87%) were males. Underlying conditions included surgery, hematologic malignancies, solid organ transplantation, and chronic pulmonary disease. Approximately one-half of patients were receiving corticosteroids or were neutropenic. Other conditions of immune impairment included chronic granulomatous disease (CGD) and diabetes mellitus.
Classification of Aspergillus arthritis and mechanisms of articular infection
Seventeen cases (55%) were proven and 14 (45%) were classified as probable Aspergillus arthritis (Table 2) . De novo Aspergillus arthritis (infection without concurrent antifungal therapy) accounted for 84% vs. breakthrough infection in 16%. Among the apparent mechanisms of Aspergillus arthritis, most cases demonstrated hematogenous dissemination (52%) and direct inoculation (39%).
Osteoarticular distribution
Monoarticular involvement occurred in 17 cases (55%), while two or more joints were infected in 14 (45%). Aspergillus arthritis involved the knee in 11 cases (35%), intervertebral discs in 8 (26%) and hip in 5 (16%) ( Table 3) . The tibia was the most frequently infected bone site.
Diagnostic procedures and microbiological identification
Arthrocentesis and open biopsy were most commonly used to establish a diagnosis of Aspergillus arthritis (Table 4) . Synovial fluid culture detected Aspergillus species in 17 (100%) of 17 cases. Culture of adjacent bone was similarly sensitive in detection of 13 (93%) of 14 cases. Aspergillus was detected histologically in approximately one-half of cases in which it was studied, while Gram-stain had low yield (18%) in detection of hyphal structures. Aspergillus fumigatus was the most common species identified by culture in 77% of cases.
Clinical manifestations
Pain and tenderness related to the infected joint in Aspergillus arthritis were the most common clinical manifestations in 87% of cases; whereas fever, edema, erythema, and decreased range of motion were less common findings ( Table 5) .
Markers of inflammation
Although the median white blood cell (WBC) count was only slightly elevated (9,700 WBCs/μL (range, 1,300-12,700)) with median %PMNs of 71 (range, 54-88), the median erythrocyte sedimentation rate (ESR) was moderately elevated at 90 mm/h and median CRP was 3.6 mg/dl (Table 5) . By comparison, the synovial fluid demonstrated a moderate degree of leukocytosis of 17,200/μl with a broad range of inflammation from 7,300 to 128,000/μl and a differential count of 61-92% PMNs. 
Diagnostic imaging
The most common radiological abnormalities were osteolysis and bone destruction in 35% (Table 6 ). Extension into soft tissues was observed in 47% of cases and adjacent osteomyelitis in 61%. Increased uptake occurred in 6 of 8 Tc99 bone scans. MRI scans were initially positive in less than one-half of cases with decreased signal intensity on T1-weighted imaging and increased signal intensity on T2-weighted imaging.
Treatment and outcome
Nineteen patients (61%) with Aspergillus arthritis were treated with antifungal therapy and surgery, 10 (32%) with antifungal agents only, and two (6%) underwent surgical intervention only ( Table 7) . The most common agent used was amphotericin B (65%) followed by itraconazole (48%). Voriconazole was used in two cases (7%). Patients received more than one antifungal agent as combination therapy in 9 cases (29%). Median duration of therapy was 219 days (range, 30-545 d). Debridement was the most common surgical procedure (61%) followed by drainage (19%), prosthesis removal (6%), and amputation (6%). Complete response of Aspergillus arthritis was achieved in 22 cases (71%), partial response in 5 (16%), relapse in 5 (16%), and death in 11 (35%) ( Table 7) . Among the 5 relapsed cases, all were subsequently treated to achieve a complete response. Among the three patients who died, two succumbed to skull-base osteomyelitis and one to disseminated aspergillosis.
Pediatric patients
Among pediatric patients with Aspergillus arthritis, there was one 12-month old infant and three boys (ages 10, 12, and 18). As predisposing factors, the infant suffered from acute leukemia with cutaneous aspergillosis that progressed to synovial fluid culture-positive Aspergillus fumigatus and A. flavus polyarthritis involving three joints and bones. Pain and tenderness were the only initial manifestations. Despite amphotericin B therapy, the child died from disseminated aspergillosis. Among the distinctive immune impairments, acute lymphoblastic leukemia was present in two and chronic granulomatous diseases (CGD) in one. All three had hematogenous infection. Two had polyarthritis (multiple intervertebral sites (T1-T3); knee, ankle, and carpal joints), while one had monoarticular hip infection. The child with CGD had intervertebral osteomyelitis with an epidural abscess. Pain and tenderness were present in all. Draining pus and sinus tract formation was present in the carpal joint. Treatment consisted of antifungal therapy and surgery in one child and antifungal therapy alone in two others.
Discussion
This study found that Aspergillus arthritis occurs predominantly in males who are either pharmacologically immunosuppressed or having undergone surgery. Joints seem to be infected most commonly either by hematogenous seeding or as de novo infection without prior antifungal therapy. Reflecting the hematogenous route, two or more joints were infected in nearly one-half of patients. Adjacent osteomyelitis was common. Clinical manifestations included pain, edema, and limited function, especially of knees and hips. By comparison, spondylodiscitis presented as localizing pain. Diagnosis was established by synovial fluid culture. Aspergillus arthritis produced an acute inflammatory synovitis and elevated ESR. Osteolytic destruction and soft tissue extension were frequently evident on diagnostic imaging. Antifungal management usually consisted of a combination of medical and surgical intervention with an extended period of therapy measured in months.
In understanding Aspergillus arthritis, a discussion of the comparative pathogenesis with Candida arthritis is warranted. 29 Aspergillus arthritis arises as a hematogenous process in immunocompromised hosts and as direct inoculation in immunocompetent patients, such as those undergoing surgery or sustaining trauma. Aspergillus arthritis also was an invasive process that extended into adjacent bone and surrounding soft tissue. This compares with the more commonly encountered Candida arthritis that is principally hematogenously distributed in 81% of cases. The pathophysiological basis for the preponderance of males in this series remains to be defined. A similar propensity of males (80%) among 180 cases of Aspergillus osteomyelitis also was observed by Gamaletsou et al. 29 and in 80% of 111 cases of non-Aspergillus mould osteoarticular infections by Taj-Aldeen et al. 30 Aspergillus arthritis and the more commonly encountered Candida arthritis are frequently caused by hematogenous dissemination to the joints. Notably, some immunocompromised patients did not have an apparent pulmonary or extra-osseous focus, suggesting that isolated Aspergillus arthritis may arise de novo in immunosuppressed hosts without prior antifungal therapy. In comparison to Candida arthritis, Aspergillus arthritis may be more frequently associated with direct inoculation in immunocompetent patients possibly as the result of an environmental contamination during trauma or surgery. This pathogenesis is shared by non-Aspergillus mould osteoarticular infections, where direct inoculation occurred in 54.5% of cases. 30 In contrast, such cases of direct inoculation in Candida arthritis are unusual. Most cases of Aspergillus and Candida arthritis arise de novo before the initiation of antifungal therapy.
However, approximately one-third of cases of Candida arthritis emerges as breakthrough infection while receiving antifungal therapy. 29 A high index of suspicion is necessary for fungal causes in the evaluation of infectious arthritis. The clinical manifestations of pain, tenderness, edema, and decreased range of motion are common for most forms of fungal and bacterial arthritis. However, erythema was an infrequent manifestation of Aspergillus arthritis. Although diagnostic imaging evidence of adjacent osteolysis and periarticular soft tissue extension was commonly observed in cases of Aspergillus arthritis, such findings are not specific. For example, soft tissue extension was also observed in Candida arthritis and may also be found in selected causes of bacterial arthritis. Moreover, there are no distinct clinical manifestations that would reliably distinguish bacterial and Aspergillus arthritidies. Instead, the constellation of clinical and imaging manifestations of possible joint infection should prompt a laboratory diagnosis as the definitive means of identification of the microbial etiology.
Since Aspergillus spp. were recovered in 17 of 17 synovial fluid cultures, these findings would suggest that arthrocentesis would be the most direct approach to establishing a diagnosis of Aspergillus arthritis. The exceptions, however, may be the hip joint, which may be more difficult to access or the intervertebral discs, which may require a biopsy of adjacent bone or soft tissue if the disc is not accessible via interventional radiology. As synovial fluid white count is typically elevated within the range of bacterial and Candida arthritis, culture becomes of paramount importance in identifying the pathogen. Since Aspergillus spp. are seldom contaminants of synovial fluid, recovery of these organisms should be considered to be pathogenic unless proven otherwise.
While the majority (61%) of patients with Aspergillus arthritis was treated with combined medical and surgical therapy, 32% received antifungal therapy alone. Evidence for soft tissue extension, osteolytic destruction, and adjacent osteomyelitis that are commonly observed in Aspergillus arthritis may be relevant indications for surgery. The median duration of therapy for Aspergillus arthritis of 219 days greatly exceeds that of 90 days observed for Candida arthritis. 29 These differences may reflect the greater propensity for Candida arthritis to be more amenable to medical therapy alone. Indeed, only 36% of cases Candida arthritis were treated with combined medical and surgical intervention. Notably, there were identical frequencies of relapse (16%) in treatment of Aspergillus arthritis and of Candida arthritis, further confirming the need for a more extended course of antifungal therapy. One should also note that relapse of Aspergillus arthritis following a course of therapy was successfully treated in all cases with a subsequent cycle of treatment. Notably, the median duration of therapy for Aspergillus arthritis is also longer than that of other osteoarticular mycoses. [29] [30] [31] [32] [33] Among the pediatric patients, leukemia and CGD were the most common predisposing factors. The frequency of CGD to the total population in this study was 1:31 in comparison to that of Aspergillus osteomyelitis where the ratio was 16:180. 29 The differences may be related to the tendency for children with CGD to extend contiguous pulmonary Aspergillus lesions commonly to ribs without joint involvement. This study of Aspergillus arthritis has several limitations. Due to its retrospective design, not all data points were uniformly acquired. Although the study may be affected by publication bias, which may lead to the reporting of better outcomes, the study design is uniquely strengthened by the detail provided through individual case reports. The comprehensive nature of the study-design from the earliest reported case to the present may introduce variations in advances of imaging and treatment; however, it also increases an understanding of mechanisms, possible risk factors, clinical manifestations, and diagnostic laboratory features. While lack of a denominator in the study design precludes establishing an estimate of incidence, this was not the objective of this study. Although a prospective, multicenter, case-controlled observational study would address these limitations, such a design for Aspergillus arthritis would require years for completion. Thus, the study design used in the current review may provide for a protocol-based selection of patients analyzed through a finely detailed database for advancing the understanding of this uncommon osteoarticular mycosis. Finally, as a reflection of the uncommon frequency of Aspergillus arthritis, only two patients were reported as having received therapy with voriconazole.
In summary, Aspergillus arthritis may develop either as a de novo infection without prior antifungal therapy involving knees, intervertebral disks, and hips in immunocompromised hosts as a hematogenous process. Aspergillus arthritis also may develop in immunocompetent patients suffering from trauma or prior surgery by contiguous infection or direct inoculation. Clinical manifestations and diagnostic imaging should raise the index of suspicion for fungal arthritis; however, a definitive diagnosis of Aspergillus arthritis is best established by synovial fluid culture. Aspergillus arthritis is usually treated with a combination of surgery and extended course of antifungal therapy. Future advances in the epidemiology, diagnosis, and treatment of Aspergillus arthritis may be achieved through a prospective registry and through animal model systems, which would elucidate novel biomarkers and introduce new pharmacodynamic approaches with novel therapeutic implications to improve management of this debilitating osteoarticular mycosis.
